Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease

Executive Summary

Germany’s leading pharmaceutical company Bayer has taken future competition into account when stopping the Phase III development of finerenone for congestive heart failure, and targeting specific CHF patients for treatment with another potential cardiovascular, vericiguat.


Related Content

Changes Brewing At Bayer, But Pharma Strategy Remains On Point
Bayer Wary Of Future Competition In Renal Anemia Market
Bayer Chief Dekkers Departs With Words Of Warning, Wisdom For Pharma


Related Companies